Citation: | Guang-Yue Li, Shu-Jing Zhang, Dong Xue, Yue-Qi Feng, Yan Li, Xun Huang, Qiang Cui, Bo Wang, Jun Feng, Tao Bao, Pei-Jun Liu, Shao-Ying Lu, Ji-Chang Wang. Overcoming chemoresistance in non-angiogenic colorectal cancer by metformin via inhibiting endothelial apoptosis and vascular immaturity[J]. Journal of Pharmaceutical Analysis, 2023, 13(3): 262-275. doi: 10.1016/j.jpha.2023.02.001 |
K.D. Miller, A.P. Ortiz, P.S. Pinheiro, et al., Cancer statistics for the US Hispanic/Latino population, CA: Cancer J. Clin. 71 (2021) 466-487.
|
X. Liu, K. Su, X. Sun, et al., Sec62 promotes stemness and chemoresistance of human colorectal cancer through activating Wnt/β-catenin pathway, J. Exp. Clin. Cancer Res. 40 (2021), 132.
|
S. Usman, M. Khawer, S. Rafique, et al., The current status of anti-GPCR drugs against different cancers, J. Pharm. Anal. 10 (2020) 517-521.
|
Y. Yin, S. Yao, Y. Hu, et al., The Immune-microenvironment Confers Chemoresistance of Colorectal Cancer through Macrophage-Derived IL6, Clin. Cancer Res. 23 (2017) 7375-7387.
|
T. Shi, Y. Ma, L. Cao, et al., B7-H3 promotes aerobic glycolysis and chemoresistance in colorectal cancer cells by regulating HK2, Cell Death Dis. 10 (2019), 308.
|
W. Zou, J.D. Wolchok, L. Chen, PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations, Sci. Transl. Med. 8 (2016), 328rv4.
|
J.J. Marin, F. Sanchez de Medina, B. Castano, et al., Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer, Drug Metab. Rev. 44 (2012) 148-172.
|
V.P. Chauhan, T. Stylianopoulos, J.D. Martin, et al., Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner, Nat. Nanotechnol. 7 (2012) 383-388.
|
F. Pezzella, K. Gatter, Non-angiogenic tumours unveil a new chapter in cancer biology, J. Pathol. 235 (2015) 384-396.
|
V.L. Bridgeman, P.B. Vermeulen, S. Foo, et al., Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models, J. Pathol. 241 (2017) 362-374.
|
S. Frentzas, E. Simoneau, V.L. Bridgeman, et al., Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases, Nat. Med. 22 (2016) 1294-1302.
|
T. Donnem, J. Hu, M. Ferguson, et al., Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?, Cancer Med. 2 (2013) 427-436.
|
Y. Shen, S. Li, X. Wang, et al., Tumor vasculature remolding by thalidomide increases delivery and efficacy of cisplatin, J. Exp. Clin. Cancer Res. 38 (2019), 427.
|
G. Arunachalam, S.M. Samuel, I. Marei, et al., Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1, Br. J. Pharmacol. 171 (2014) 523-535.
|
S. Frentzas, E. Simoneau, V.L. Bridgeman, et al., Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases, Nat. Med. 22 (2016) 1294-1302.
|
B. Strilic, L. Yang, J. Albarran-Juarez, et al., Tumour-cell-induced endothelial cell necroptosis via death receptor 6 promotes metastasis, Nature 536 (2016) 215-218.
|
T. Salvatore, P.C. Pafundi, R. Galiero, et al., Can Metformin Exert as an Active Drug on Endothelial Dysfunction in Diabetic Subjects?, Biomedicines 9 (2020), 3.
|
L. Eriksson, T. Nystrom, Activation of AMP-activated protein kinase by metformin protects human coronary artery endothelial cells against diabetic lipoapoptosis, Cardiovasc. Diabetol. 13 (2014), 152.
|
Y. Ding, Y. Zhou, P. Ling, et al., Metformin in cardiovascular diabetology: a focused review of its impact on endothelial function, Theranostics 11 (2021) 9376-9396.
|
C. Rolny, M. Mazzone, S. Tugues, et al., HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF, Cancer cell 19 (2011) 31-44.
|
G. Peter, T. Wagner, H.J. Hohorst, Studies on 4-hydroperoxycyclophosphamide (NSC-181815): a simple preparation method and its application for the synthesis of a new class of "activated" sulfur-containing cyclophosphamide (NSC-26271) derivatives, Cancer Treat. Rep. 60 (1976) 429-435.
|
J.C. Wang, G.Y. Li, Y. Wang, et al., Suppression of tumor angiogenesis by metformin treatment via a mechanism linked to targeting of HER2/HIF-1alpha/VEGF secretion axis, Oncotarget 6 (2015) 44579- 44592.
|
J.C. Wang, X.X. Li, X. Sun, et al., Activation of AMPK by simvastatin inhibited breast tumor angiogenesis via impeding HIF-1α-induced pro-angiogenic factor, Cancer Sci. 109 (2018) 1627-1637.
|
J.C. Wang, G.Y. Li, B. Wang, et al., Metformin inhibits metastatic breast cancer progression and improves chemosensitivity by inducing vessel normalization via PDGF-B downregulation, J. Exp. Clin. Cancer Res. 38 (2019), 235.
|
J.C. Wang, G.Y. Li, P.P. Li, et al., Suppression of hypoxia-induced excessive angiogenesis by metformin via elevating tumor blood perfusion, Oncotarget 8 (2017) 73892-73904.
|
J.C. Wang, X. Sun, Q. Ma, et al., Metformin's antitumour and anti-angiogenic activities are mediated by skewing macrophage polarization, J. Cel. Mol. Med. 22 (2018) 3825-3836.
|
H. Maes, A. Kuchnio, A. Peric, et al., Tumor vessel normalization by chloroquine independent of autophagy, Cancer cell 26 (2014) 190-206.
|
J. Holash, P.C. Maisonpierre, D. Compton, et al., Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF, Science 284 (1999) 1994-1998.
|
V. Szabo, E. Bugyik, K. Dezso, et al., Mechanism of tumour vascularization in experimental lung metastases, J. Pathol. 235 (2015) 384-396.
|
E. Passalidou, M. Stewart, M. Trivella, et al., Vascular patterns in reactive lymphoid tissue and in non-Hodgkin's lymphoma, Br. J. Cancer 88 (2003) 553-559.
|
E. Bridges, A.L. Harris, Vascular-promoting therapy reduced tumor growth and progression by improving chemotherapy efficacy, Cancer cell 27 (2015) 7-9.
|
X. Han, B. Wang, Y. Sun, et al., Metformin Modulates High Glucose-Incubated Human Umbilical Vein Endothelial Cells Proliferation and Apoptosis Through AMPK/CREB/BDNF Pathway, Front. Pharmacol. 9 (2018), 1266.
|
E. Durand, A. Scoazec, A. Lafont, et al., In Vivo Induction of Endothelial Apoptosis Leads to Vessel Thrombosis and Endothelial Denudation A Clue to the Understanding of the Mechanisms of Thrombotic Plaque Erosion, Circulation 109 (2004) 2503-2506.
|
J. Davignon, P. Ganz, Role of endothelial dysfunction in atherosclerosis, Circulation 109 (2004) III-27-III-32.
|
G.M. Tozer, C. Kanthou, B.C. Baguley, Disrupting tumour blood vessels, Nat. Rev. Cancer 5 (2005) 423-435.
|
P.P. Wong, F. Demircioglu, E. Ghazaly, et al., Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread, Cancer Cell 27 (2015) 123-137.
|
S. Schoors, U. Bruning, R. Missiaen, et al., Fatty acid carbon is essential for dNTP synthesis in endothelial cells, Nature 520 (2015) 192-197.
|
J. Incio, J. Tam, N.N. Rahbari, et al., PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity, Clin. Cancer Res. 22 (2016) 2993-3004.
|
H. Xie, Z. Cui, L. Wang, et al., PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis, Nat. Med. 20 (2014) 1270-1278.
|
M. Bai, L. Yang, H. Liao, et al., Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism, Oncogene 37 (2018) 5666-5681.
|
L. Li, R. Han, H. Xiao, et al., Metformin Sensitizes EGFR-TKI-Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal, Clin. Cancer Res. 20 (2014) 2714-2726.
|
Y.W. Choi, I.K. Lim, Sensitization of metformin-cytotoxicity by dichloroacetate via reprogramming glucose metabolism in cancer cells, Cancer lett. 346 (2014) 300-308.
|
V.L. Bridgeman, P.B. Vermeulen, S. Foo, et al., Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models, J. Pathol. 241 (2017) 362-374.
|
H.S. Jeong, D. Jones, S. Liao, et al., Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases, J. Natl. Cancer Inst. 107 (2015), djv155.
|
G. Bergers, D. Hanahan, Modes of resistance to anti-angiogenic therapy, Nat. Rev. Cancer 8 (2008) 592-603.
|
E. Passalidou, M. Trivella, N. Singh, et al., Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas, Br. J. Cancer 86 (2002) 244-249.
|
S. Orecchioni, F. Reggiani, G. Talarico, et al., The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells, Int. J. Cancer 136 (2014) E534-E544.
|
W. Qian, J. Li, K. Chen, et al., Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer, Life Sci. 208 (2018) 253-261.
|
S. Goel, D.G. Duda, L. Xu, et al., Normalization of the vasculature for treatment of cancer and other diseases, Physiol. Rev. 91 (2011) 1071-1121.
|